KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Thermo Fisher Scientific (TMO) EBT (2016 - 2026)

Thermo Fisher Scientific filings provide 18 years of EBT readings, the most recent being $1.7 billion for Q1 2026.

  • On a quarterly basis, EBT rose 7.04% to $1.7 billion in Q1 2026 year-over-year; TTM through Mar 2026 was $7.4 billion, a 5.01% increase, with the full-year FY2025 number at $7.3 billion, up 3.85% from a year prior.
  • EBT hit $1.7 billion in Q1 2026 for Thermo Fisher Scientific, down from $2.2 billion in the prior quarter.
  • In the past five years, EBT ranged from a high of $2.5 billion in Q2 2022 to a low of $1.4 billion in Q2 2023.
  • Median EBT over the past 5 years was $1.7 billion (2024), compared with a mean of $1.8 billion.
  • Biggest five-year swings in EBT: plummeted 46.34% in 2023 and later grew 23.43% in 2024.
  • Thermo Fisher Scientific's EBT stood at $1.8 billion in 2022, then dropped by 2.08% to $1.7 billion in 2023, then rose by 11.55% to $1.9 billion in 2024, then grew by 10.92% to $2.2 billion in 2025, then fell by 19.46% to $1.7 billion in 2026.
  • The last three reported values for EBT were $1.7 billion (Q1 2026), $2.2 billion (Q4 2025), and $1.8 billion (Q3 2025) per Business Quant data.